News

In episode 1 of this short video series, a clinician discusses his experience in what his institution is seeing as well as how they handle their treatment protocol and stewardship where possible.

16 people have been reported to be infected across 6 states resulting in one death and a pregnancy loss in an expecting mother who became infected.

In Boston school districts, lifting mask mandates was correlated with an additional 44.9 COVID-19 infections per 1000 students and staffers.

The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.

HIV PrEP prescriptions increased from 0 among people who use injection drugs, but overall PrEP uptake remains low.

Initially, 28-29% of patients with chronic hepatitis B achieved undetectable virus levels after 24 weeks of treatment with GSK’s bepirovirsen, but this dropped to 9-10% of patients during a phase 2b trial.

The World Health Organization's fungal priority pathogens list is intended to prompt research, development and policy against the increasing health threat.

About a third of veterans who received a letter to get tested for hepatitis C did so, according to a study by the Veterans Affairs Greater Los Angeles Healthcare System.

Studies suggest young women’s substance use is catching up to men's. Tammy Chung, PhD, examined whether this was exacerbated by the COVID-19 pandemic.

Frontier Biotechnologies reported data from its phase 1 trial for its investigational therapy, FB2001, for patients exposed to the virus.

The benefits to children of wearing face masks to prevent COVID-19 outweigh potential infectious risks from face touching, according to a study analyzing hand-to-face contact in a simulated school environment.

The intranasal, live-attenuated vaccine CodaVax-RSV was granted FDA Fast Track designation. Clinical trials are expected to launch soon.

Experts discuss a range of the most topical infectious disease research, presented at the recent IDWeek 2022 conference.

The study authors called eliminating barriers to HIV care and treatment a national priority.

November is Clostridioides difficile (C diff) awareness month. The Peggy Lillis Foundation hopes to use the month to increase the public’s awareness of the dangers of the infection.

In communities of color, hesitancy, mistrust, and access issues all drove low COVID-19 vaccination rates during the pandemic.

Previously thought to be difficult or impossible, one study found HCV and drug use can be treated concurrently in young adults.

Dengue is the most prevalent and important mosquito-borne virus in the world. Atea Pharmaceuticals presented positive data for their direct-acting dengue antiviral, AT-752.

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.

Vaxxinity is moving forward with research to bring its UB-612 COVID-19 vaccine to market as a mix-and-match booster to authorized vaccines.

How do we increase HIV PrEP uptake? “I think the biggest takeaway here is that people need options,” said Travis Sanchez, DVM, MPH.

Pregnant people taking dolutegravir were more likely to achieve HIV viral suppression and less likely to have a preterm birth than participants using other forms of ART.

There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.

Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.

Is it safe and beneficial to administer a second immunomodulator in patients with moderate COVID-19? How do we identify which patients are likely to progress to severe disease?

Lodise breaks down significant findings from his 8 IDWeek 2022 posters.

Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to respiratory syncytial virus (RSV) in infants from birth through the first 90 days of life.

Remdesivir was the first FDA-approved drug to fight COVID-19, but how has it held up against the latest variants?

“In the long run, what we will have is a virus that will become endemic in our population," said Donald J. Alcendor, MD. "The idea of thinking we can chase variants with boosters is a failed effort. We must realize that.”

Prevymis showed less leukopenia and neutropenia compared to valganciclovir during the trial.